Avior Wealth Management LLC boosted its position in Elevance Health, Inc. (NYSE:ELV – Free Report) by 10.4% during the 4th quarter, according to the company in its most recent filing with the ...

Before making this announcement, Elevance Health was easily earning enough to cover the dividend. As a result, a large proportion of what it earned was being reinvested back into the business.

Whit Mayo, an analyst from Leerink Partners, reiterated the Buy rating on Elevance Health (ELV – Research Report). The associated price target is $463.00. Whit Mayo has given his Buy rating due ...

In a report released today, Stephen Baxter from Wells Fargo maintained a Buy rating on Elevance Health (ELV – Research Report), with a price target of $478.00. The company’s shares closed ...

Analysts' ratings for Elevance Health ELV over the last quarter vary from bullish to bearish, as provided by 6 analysts. Summarizing their recent assessments, the table below illustrates the ...

Unless the payments are sustainable, the dividend yield doesn't mean too much. Before making this announcement, Elevance Health was easily earning enough to cover the dividend. As a result, a large ...

Elevance Health remains one of the leading health insurers in the U.S., providing medical benefits to 47 million medical members as of December 2023. The company offers employer, individual ...

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx ...